BioSight

Company Overview

Snapshot

Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.

Business overview

BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is an anti-metabolite designed to deliver high-dose therapy with reduced systemic toxicity. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and biopharmaceutical industries with its cancer and chemotherapy treatments.

Strategic signal

In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation. This development signals the company's continued commitment to advancing its lead product and exploring combination therapies to improve outcomes for acute myeloid leukemia patients, demonstrating ongoing clinical validation and potential for market expansion prior to its acquisition.

Company Intelligence Q&A

What was BioSight's most significant corporate event?

In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the company and its investors.

When did BioSight secure its Series C funding?

In March 2020, BioSight secured $19M in Series C funding. Israel Biotech Fund led this round, with participation from Arkin Bio.

What was a key regulatory milestone for BioSight's lead product?

In June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of Acute Myeloid Leukemia, highlighting the product's potential in addressing a rare disease.

What clinical trial was launched in late 2022?

In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation.

Did BioSight receive any other FDA designations for BST-236?

In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia, aiming to expedite the development and review of the drug.